Literature DB >> 33486322

Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.

Qianhui Xu1, Yuxin Wang2, Wen Huang3.   

Abstract

BACKGROUND: An increasing body of evidence has supported that long non-coding RNAs (lncRNAs) can play as essential roles of various physiological process and pathological diseases. We aimed to construct a robust immune-associated lncRNA signature associated with the prognosis for HCC survival prediction.
METHODS: 7 immune-associated lncRNAs presenting significant correlation with survival were screened through stepwise univariate Cox regression and LASSO algorithm, and multivariate Cox regression. Kaplan-Meier analysis, proportional hazards model, and ROC analyses further conducted. Gene set enrichment analysis (GSEA) was applied for functional annotation. We conducted quantitative real-time polymerase chain reaction to determine NRAV expression and preliminarily explored the latent role of NRAV in prognosis of HCC patients.
RESULTS: Finally, 7 immune-related lncRNA signature composed of AC007405.3, AC023157.3, NRAV, CASC19, MSC-AS1, GASAL1, and LINC00942 were validated. This lncRNAs signature can serve as an independent predictive biomolecular factor. This signature was further confirmed in the validation group and the entire cohort. We demonstrated that NRAV was significantly upregulated in HCC cell lines and it may serve as a key regulator in HCC. Our signature was associated to apoptosis and immunologic characteristics. This signature mediated immune cell infiltration (i.e., Dendritic, etc.,) and immune checkpoint blockade (ICB) immunotherapy-related molecules (i.e., CD274, etc.,).
CONCLUSION: This immune-related lncRNA signature possesses promising prognostic value in HCC and may have the potentiality to predict clinical outcome of ICB immunotherapy.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; Immune; Immune cell infiltration; Immune checkpoint blockade; Long non-coding RNAs; Prognosis analysis

Mesh:

Substances:

Year:  2021        PMID: 33486322     DOI: 10.1016/j.intimp.2020.107333

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  28 in total

1.  NUF2 Is a Potential Immunological and Prognostic Marker for Non-Small-Cell Lung Cancer.

Authors:  Xia Li; Lianlian Zhang; Zhongquan Yi; Jing Zhou; Wenchun Song; Panwen Zhao; Jixiang Wu; Jianxiang Song; Qinggan Ni
Journal:  J Immunol Res       Date:  2022-05-12       Impact factor: 4.493

2.  Novel γδ T cell-based prognostic signature to estimate risk and aid therapy in hepatocellular carcinoma.

Authors:  Jingrui Wang; Sunbin Ling; Jie Ni; Yafeng Wan
Journal:  BMC Cancer       Date:  2022-06-10       Impact factor: 4.638

3.  A Novel Matrisomal-Related LncRNA Signature Associated With Survival Outcome and Immune Evasion in Patients With Gastric Cancer.

Authors:  Yuan Yang; Li Shi; Jun Zhang; Ya Zheng; Guozhi Wu; Jie Sun; Min Liu; Zhaofeng Chen; Yuping Wang; Rui Ji; Qinghong Guo; Yongning Zhou
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

4.  Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.

Authors:  Shenglan Huang; Jian Zhang; Xiaolan Lai; Lingling Zhuang; Jianbing Wu
Journal:  Front Mol Biosci       Date:  2021-12-24

Review 5.  Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Alessandro Di Federico; Giorgio Frega; Andrea Palloni; Simona Tavolari; Giovanni Brandi
Journal:  Front Oncol       Date:  2021-12-17       Impact factor: 6.244

6.  Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma.

Authors:  Xigang Xia; Hao Zhang; Peng Xia; Yimin Zhu; Jie Liu; Kequan Xu; Yufeng Yuan
Journal:  Front Oncol       Date:  2021-08-30       Impact factor: 6.244

7.  Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma.

Authors:  Qianhui Xu; Hao Xu; Rongshan Deng; Zijie Wang; Nanjun Li; Zhixuan Qi; Jiaxin Zhao; Wen Huang
Journal:  Cancer Cell Int       Date:  2021-07-03       Impact factor: 5.722

8.  Use of 6 m6A-relevant lncRNA genes as prognostic markers of primary liver hepatocellular carcinoma based on TCGA database.

Authors:  Xiao-Li Zhu; Qing Li; Jie Shen; Li Shan; Er-Dong Zuo; Xu Cheng
Journal:  Transl Cancer Res       Date:  2021-12       Impact factor: 1.241

9.  Aerial View of the Association Between m6A-Related LncRNAs and Clinicopathological Characteristics of Pancreatic Cancer.

Authors:  Bowen Huang; Jianzhou Liu; Jun Lu; Wenyan Gao; Li Zhou; Feng Tian; Yizhi Wang; Mingjie Luo; Dong Liu; Congyong Xie; Ziyu Xun; Chengxi Liu; Yu Wang; Haibo Ma; Junchao Guo
Journal:  Front Oncol       Date:  2022-01-03       Impact factor: 6.244

10.  Immunoautophagy-Related Long Noncoding RNA (IAR-lncRNA) Signature Predicts Survival in Hepatocellular Carcinoma.

Authors:  Yulu Wang; Fangfang Ge; Amit Sharma; Oliver Rudan; Maria F Setiawan; Maria A Gonzalez-Carmona; Miroslaw T Kornek; Christian P Strassburg; Matthias Schmid; Ingo G H Schmidt-Wolf
Journal:  Biology (Basel)       Date:  2021-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.